List of Excipients in Branded Drug ADREVIEW

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medi-Physics Inc	ADREVIEW	iobenguane i-123	17156-235	BENZYL ALCOHOL
Medi-Physics Inc	ADREVIEW	iobenguane i-123	17156-235	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE
Medi-Physics Inc	ADREVIEW	iobenguane i-123	17156-235	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE

ADreView Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

ADreView is iobenguane I-123 injection, a diagnostic radiopharmaceutical used for scintigraphic imaging of adrenergic tissue, including neuroblastoma and selected pheochromocytoma and paraganglioma cases. Its commercial value is driven less by conventional formulation differentiation than by isotope access, manufacturing reliability, radiochemical stability, sterile packaging, distribution timing, and hospital workflow.

The principal excipient opportunity is to improve preservative strategy, container-closure performance, radiolysis control, pediatric suitability, and ready-to-use presentation without compromising image quality, sterility, radiochemical purity, or the short I-123 supply window.

What is ADreView and what excipients does it contain?

ADreView is an intravenous solution containing iobenguane sulfate labeled with iodine-123. I-123 has a physical half-life of approximately 13.2 hours, making the product highly time-sensitive from manufacture through administration.[1]

The U.S. prescribing information identifies benzyl alcohol as a preservative in the formulation.[2] The product is supplied as a sterile, nonpyrogenic radiopharmaceutical injection. The approved presentation is designed for direct clinical use rather than bedside reconstitution.

Attribute	ADreView profile
Active ingredient	Iobenguane sulfate I-123
Therapeutic category	Diagnostic radiopharmaceutical
Route	Intravenous injection
Primary uses	Imaging of adrenergic tissue, including neuroblastoma and pheochromocytoma/paraganglioma applications
Radionuclide	Iodine-123
Physical half-life	Approximately 13.2 hours
Preservative identified in labeling	Benzyl alcohol
Product type	Sterile injectable solution
Core commercial constraint	Isotope production, release, shipping, and administration within a narrow time window

Benzyl alcohol provides a familiar preservative system for a multidose or controlled-use injectable presentation, but it creates a potential differentiation issue for pediatric imaging. Benzyl alcohol exposure has been associated with toxicity concerns in neonates and infants, particularly when exposure is substantial or repeated.[3] The product label therefore requires age- and dose-sensitive risk assessment.

What excipient strategy best fits ADreView?

The strongest strategy is not to add multiple excipients. It is to create a controlled formulation platform with a clear clinical and regulatory rationale.

Preservative-free presentation

A preservative-free, single-dose ADreView-compatible presentation could address the principal formulation concern associated with benzyl alcohol. The commercial benefit would be greatest in pediatric neuroblastoma imaging and institutions seeking to reduce preservative exposure.

A preservative-free product would require:

• Single-dose vial or prefilled syringe configuration
• Validated sterile manufacturing and aseptic filling
• Demonstrated container-closure integrity
• Defined in-use period and discard policy
• Radiochemical stability through the labeled administration window
• Compatibility with automated dose-dispensing systems
• Pediatric safety justification

The main disadvantage is higher packaging and fill-finish cost. A preservative-free product also removes the formulation margin provided by a preservative in the event of repeated vial access. The commercial design should therefore pair preservative-free formulation with a single-use container.

Low-excipient aqueous system

For a radiopharmaceutical with a short half-life, a low-excipient formulation has several advantages:

• Fewer components to qualify and control
• Lower risk of radiochemical interaction
• Lower extractables and leachables burden
• Simpler global regulatory documentation
• Reduced risk of injection-site tolerability issues
• Easier technology transfer to radiopharmacy or centralized manufacturing sites

The formulation should maintain appropriate pH, osmolality, sterility, endotoxin control, and radiochemical purity. The excipient package should not be expanded unless each component solves a defined stability or usability problem.

Radiolysis-control strategy

Ionizing radiation can promote radiolysis of the drug substance, solvent, container components, and trace impurities. A commercial development program could evaluate radiolysis-control excipients, including antioxidant or radical-scavenging systems, but this route carries substantial regulatory and technical risk.

A new radiolysis-control excipient would need data on:

• Chemical compatibility with iobenguane
• Effect on iodine-123 labeling chemistry
• Radiochemical purity over the product shelf life
• Degradation products and toxicological qualification
• Image quality and biodistribution
• Compatibility with vial, stopper, syringe, and shielding materials

In many cases, container selection, oxygen control, light protection, manufacturing timing, and cold-chain management may provide a cleaner solution than adding a new excipient.

Buffer and tonicity control

A buffer or tonicity agent may be commercially useful if it improves injection tolerability or stabilizes the product. However, the benefit must be weighed against additional impurities, interaction with the radiolabeled compound, and global regulatory complexity.

The preferred approach is a minimal system with documented control of:

• pH
• Osmolality
• Ionic strength
• Particulate matter
• Radiochemical impurities
• Chemical degradation products

What formulation patents could protect an ADreView-compatible product?

The most defensible intellectual-property strategy would focus on a differentiated formulation and delivery system rather than attempting to claim iobenguane I-123 broadly.

Potential claim categories include:

Claim area	Commercial relevance	Patent strength potential
Preservative-free iobenguane I-123 injection	Pediatric and single-dose positioning	Moderate if linked to defined stability and safety data
Low-oxygen or oxygen-controlled formulation	Radiolysis management	Moderate
Specific pH or excipient ranges	Stability and tolerability	Low to moderate unless unexpected results are shown
Prefilled syringe or unit-dose cartridge	Workflow and dose accuracy	Moderate
Container-closure system	Shelf-life and radiochemical purity	Moderate
Shielded ready-to-administer package	Radiation safety and logistics	Moderate
Automated dose-calibration workflow	Hospital operations	Moderate, often vulnerable to design-around
Manufacturing and release method	Quality and production control	Moderate to strong if process-specific
Pediatric dosing and administration method	Clinical use	Variable, depending on claim scope and prior art

A formulation patent should link the excipient or packaging choice to measurable performance: longer usable radiochemical stability, lower impurity formation, improved container compatibility, reduced preservative exposure, or a clinically relevant workflow benefit.

Broad claims to "iobenguane I-123 with an excipient" would likely face substantial prior-art exposure. Narrower claims covering a defined preservative-free composition, specific container closure, or stability profile would have better commercial value.

What is the FDA regulatory status of ADreView?

ADreView received FDA approval as a diagnostic radiopharmaceutical under NDA 022494.[2] Its regulatory status is governed by the approved labeling, current manufacturing controls, radiopharmaceutical quality requirements, and applicable FDA requirements for sterile injectable products.

A materially different excipient strategy would generally require a regulatory submission rather than a simple manufacturing change. The pathway would depend on the extent of the change:

• Minor process or supplier change: comparability and chemistry, manufacturing, and controls documentation
• New container or closure: extractables, leachables, integrity, stability, and compatibility data
• Preservative removal: antimicrobial-preservation rationale, sterility assurance, in-use studies, and stability package
• New dosage form or delivery device: device compatibility, dose accuracy, human factors, and potentially a supplemental approval
• New formulation with a new excipient: full qualification, safety, stability, and product-performance assessment

Radiopharmaceutical changes also require attention to radionuclide-specific release testing. Important controls include identity, activity, radionuclidic purity, radiochemical purity, chemical purity, sterility, endotoxins, and particulate matter.

What commercial opportunities exist for ADreView excipients and packaging?

The highest-value opportunities are adjacent to the active pharmaceutical ingredient and are tied to hospital economics.

Pediatric preservative-reduced imaging

Neuroblastoma is the clearest target for a preservative-free or benzyl-alcohol-free presentation. A pediatric-focused package could include:

• Single-dose vial
• Preservative-free aqueous formulation
• Low dead-volume syringe
• Reduced residual volume
• Clear activity labeling at calibration and expiration
• Dose-specific shielding
• Administration instructions for nuclear medicine departments

This positioning would not necessarily increase the number of scans, but it could improve institutional preference and support premium pricing where the formulation reduces handling or preservative concerns.

Ready-to-use unit doses

A ready-to-use unit-dose format could reduce nuclear medicine labor, dose-drawing errors, contamination risk, and waste. It may be more valuable than an excipient change alone.

Commercial design options include:

• Single-patient syringe
• Unit-dose vial with integrated shield
• Precalibrated dose label
• Barcoded activity and expiration information
• Tamper-evident closure
• Standardized connection to dose administration systems

The short I-123 half-life makes inventory management critical. A ready-to-use presentation has value only if distribution and scheduling are synchronized with clinical appointments.

Improved container-closure systems

The container is a central part of the product strategy because radiopharmaceuticals are shipped and stored under conditions that can stress the closure system. Opportunities include:

• Low-sorption vial and syringe materials
• Improved stopper compatibility
• Lower extractables and leachables
• Better resistance to radiolysis-related degradation
• More reliable activity retention
• Shielded packaging that reduces handling time

A container-closure patent may be commercially stronger than a narrow excipient patent if it produces measurable stability or workflow gains.

Global supply and regional fill-finish

ADreView-compatible products may support regional manufacturing models in which the nonradioactive precursor or formulation is produced centrally and radiolabeling or final fill-finish occurs closer to the clinical market. This can reduce decay-related waste and improve availability.

The model requires:

• Reliable iodine-123 supply
• Qualified radiopharmaceutical manufacturing sites
• Validated labeling and release procedures
• Regional regulatory approvals
• Coordinated logistics with nuclear medicine centers
• Short, predictable transit times

The commercial barrier is operational rather than purely formulation-based. A superior excipient system cannot compensate for unreliable radionuclide supply.

How strong is the patent estate for an ADreView formulation?

The core active ingredient is unlikely to provide a durable exclusivity strategy by itself. Iobenguane is an established chemical entity, and iodine-123 diagnostic use has a mature prior-art field.

The strongest protectable areas are likely to be:

1. A preservative-free formulation with demonstrated stability and pediatric-use advantages.
2. A specific container-closure system that preserves radiochemical purity.
3. A prefilled or unit-dose delivery configuration.
4. A manufacturing process that controls radiolysis or improves lot release.
5. A defined combination of formulation, packaging, and time-to-administration parameters.

The weakest areas are likely to be generic claims covering conventional buffers, isotonic agents, or standard sterile injectable excipients without unexpected performance data.

A freedom-to-operate review should cover U.S., European, Japanese, and major radiopharmaceutical markets. The review should include formulation patents, container patents, device patents, manufacturing claims, and method-of-use claims involving neuroblastoma, pheochromocytoma, paraganglioma, and therapeutic planning.

What Orange Book, generic, and biosimilar risks apply to ADreView?

ADreView is a small-molecule radiopharmaceutical, not a biologic. Biosimilar risk is therefore not applicable. Competitive risk would arise from an abbreviated or full generic injectable, an alternative iobenguane I-123 product, or an in-house radiopharmacy preparation where legally and operationally permitted.

Potential entry pathways include:

• Abbreviated New Drug Application for a sufficiently comparable product
• 505(b)(2) application for a formulation, container, or administration difference
• Compounded or institutionally prepared radiopharmaceutical, subject to applicable law and quality requirements
• Alternative diagnostic radiopharmaceuticals targeting similar clinical questions

The Orange Book should be checked for current patent and exclusivity listings associated with the relevant NDA. Formulation and method-of-use patents may create litigation risk only if listed or otherwise enforceable against a proposed entrant. A market entrant should assess paragraph IV exposure, labeling carve-outs, non-infringing formulation design, and the timing of FDA approval relative to any remaining enforceable claims.

Because I-123 products are time-sensitive and require specialized manufacturing, practical market entry can be harder than regulatory approval alone suggests. A competing product needs isotope access, an approved or licensed radiopharmaceutical facility, quality systems, pharmacy distribution, and hospital account coverage.

How does ADreView compare with competing diagnostic options?

ADreView competes within a narrower market than conventional contrast agents and PET tracers. Its principal differentiation is adrenergic-tissue imaging with iobenguane uptake.

Factor	ADreView	Alternative diagnostic approach
Imaging target	Adrenergic tissue	Depends on tracer and modality
Radionuclide	Iodine-123	May include fluorine-18, gallium-68, technetium-99m, or others
Workflow	Nuclear medicine imaging with timed administration	Varies by modality
Formulation differentiation	Limited by short half-life and injectable use	May offer greater room for kit or PET formulation innovation
Supply risk	High because of isotope decay	Depends on radionuclide production network
Pediatric opportunity	Material in neuroblastoma imaging	Competes with alternative functional imaging methods
Commercial moat	Manufacturing, isotope access, distribution, clinical adoption	Often based on tracer availability, reimbursement, and diagnostic performance

The commercial opportunity is strongest where ADreView is embedded in a defined clinical pathway and where a competing tracer does not provide an equivalent diagnostic or treatment-planning role.

What licensing and partnership opportunities exist?

The most practical licensing opportunities involve capabilities rather than the ADreView brand alone.

Potential partners include:

• Iodine-123 producers
• Radiopharmaceutical contract manufacturers
• Sterile fill-finish organizations
• Prefilled syringe and shielding suppliers
• Nuclear medicine distributors
• Hospital automation vendors
• Diagnostic imaging companies with neuroendocrine oncology portfolios

A licensing deal could cover a preservative-free formulation, a container-closure technology, a regional manufacturing process, or a ready-to-use dose platform. Commercial terms would likely depend on territory, isotope procurement responsibility, manufacturing obligations, minimum volumes, and regulatory ownership.

An agreement that controls isotope supply may have greater economic value than a narrow excipient license. The principal reason is that product availability is constrained by decay, scheduling, and shipping reliability.

What generic launch scenarios and revenue risks exist?

A competing product could enter through one of three scenarios:

Formulation-equivalent entry

A competitor matches the active ingredient and presentation while offering lower price. This would create the highest direct price pressure but may be difficult to execute because of isotope logistics and specialized manufacturing.

Differentiated pediatric entry

A competitor launches a preservative-free, single-dose product. This could capture pediatric accounts and hospitals with strict preservative-reduction policies even at a premium.

Workflow-led entry

A competitor offers prefilled unit doses, integrated shielding, barcode traceability, and more predictable delivery. The product could win business through reduced labor and waste rather than through an excipient advantage.

Revenue exposure should be modeled against:

• Number of administered doses
• Average selling price
• Pediatric versus adult case mix
• Geographic distribution
• Isotope procurement cost
• Product wastage from cancellations or shipping delays
• Hospital contracting terms
• Availability of competing functional imaging agents

Key Takeaways

• ADreView is iobenguane I-123 injection, a sterile diagnostic radiopharmaceutical with a short isotope half-life.
• Benzyl alcohol is identified as a preservative in the U.S. labeling.
• The clearest excipient opportunity is a preservative-free, single-dose presentation aimed at pediatric and high-control hospital settings.
• Container-closure, prefilled-dose, shielding, and logistics technologies may provide stronger commercial differentiation than a new buffer or antioxidant.
• I-123 supply, manufacturing capacity, release testing, and distribution timing are major barriers to entry.
• ADreView is a small-molecule radiopharmaceutical, so biosimilar risk does not apply.
• Patent value is likely to center on formulation, packaging, manufacturing, and delivery claims rather than broad claims to iobenguane I-123.
• A 505(b)(2) or abbreviated pathway may be relevant for a differentiated formulation, depending on the proposed product and FDA determination.
• The most credible commercial strategy combines preservative reduction, unit-dose delivery, pediatric usability, and reliable isotope logistics.

FAQs

Can benzyl alcohol be removed from ADreView without changing the active ingredient?

Yes, a preservative-free formulation could retain iobenguane I-123 as the active ingredient. The change would require supporting data for sterility assurance, stability, container closure, in-use handling, and product quality.

Is a prefilled syringe commercially attractive for iobenguane I-123?

Yes, if the syringe can maintain dose accuracy, radiochemical purity, sterility, shielding compatibility, and delivery within the short I-123 half-life. The greatest value is likely to come from reduced nuclear medicine handling and lower dose-drawing waste.

What excipient has the best commercial potential for ADreView?

No single new excipient is clearly superior. The strongest opportunity is an excipient-minimized, preservative-free system supported by improved packaging and controlled oxygen or light exposure.

Can a competing company patent an ADreView pediatric formulation?

Potentially. Patentability would depend on novelty, nonobviousness, claim scope, and evidence that the formulation provides a meaningful technical or clinical advantage over known iobenguane I-123 products.

What is the largest non-formulation barrier to ADreView competition?

Reliable iodine-123 supply and time-controlled distribution are the largest barriers. Product quality and formulation matter, but a competitor also needs specialized production, regulatory infrastructure, hospital access, and coordinated radiopharmacy logistics.

References

1. International Atomic Energy Agency. (n.d.). Iodine-123 radiopharmaceuticals and nuclear medicine applications. IAEA.

2. U.S. Food and Drug Administration. (2011). ADreView (iobenguane sulfate I 123 injection) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). Inactive ingredient database and benzyl alcohol safety information. FDA.